HOPE IS ON THE HORIZON
Using metabolomics and machine learning, Olaris ® develops in vitro diagnostics that empower patients, providers, and biopharma to pursue the most effective treatments.
We get the right therapy to the right patient at the right time.
View our presentation on myOLARIS-KTdx™ at the American Transplant Congress 2022 meeting:
"By identifying a person’s “biomarkers of response” (BoR), we can determine which patients will benefit from a specific therapy to optimize outcomes and reduce adverse events."
Dr. Elizabeth O’Day, CEO & Founder, Olaris, Inc
WHY WE NEED BIOMARKERS
Precision medicine uses a patient's molecular makeup to guide individual health decisions. In our blood are biomarkers (DNA, RNA, protein, and metabolites) that make us who we are as individuals. These biomarkers help us understand why certain people are susceptible to a disease while others are not. Biomarkers also explain why if two people have the same disease and are treated with the exact same drug, one may see promising results while the other may see no effect or may even be harmed by that drug.
Unfortunately, we live in a world of "imprecision medicine," where often, the patients who do not benefit from a specific drug greatly outnumber those who do. Biomarkers of response can avoid these harmful effects and useless drug prescriptions.
PERCENTAGE OF PATIENTS FOR WHICH A
PARTICULAR DRUG IS EFFECTIVE
Spear, B.B., et al., (2001) Clinical Trends in Molecular Medicine. 7(5); 201-204
WE GET THE RIGHT DRUG TO THE RIGHT PATIENT AT THE RIGHT TIME
We are revolutionizing how diseases are diagnosed and treated by combining metabolomics and machine learning to develop precision diagnostics for the entire patient journey.
We remove the guesswork from medicine.